CANCER-TESTIS GENES ARE EXPRESSED IN T-CELL LYMPHOMAS
(Abstract release date: 05/21/15)
EHA Library. Misyurin V. 06/12/15; 102974; PB1940
Disclosure(s): Federal State Budgetary Science Institution 'N.N.Blokhin Russian Cancer Research Center'
Mr. Vsevolod Misyurin
Contributions
Contributions
Abstract
Abstract: PB1940
Type: Publication Only
Background
Several types of T-cell lymphomas are characterized by a high risk of relapse after standard chemotherapy. It continues to be reasonable to investigate potential targets for immunotherapy in T-cell lymphomas. CTG are expressed in some hematologic malignancies. Nowadays there are a few information about the CTG expression in T-cell lymphomas.
Aims
To investigate the expression profile of CTG in T-cell lymphomas.
Methods
We used RQ PCR to evaluate mRNA expression of CTG’s HAGE, NY-ESO-1, MAGEA1, PASD1, SCP1, SEMG1, SPANXA1, SSX1 and PRAME relatively gene Abl. Systems of specific primers and fluorescent probes were used for each gene. mRNA has been extracted from peripheral blood (PB), marrow (BM) and lymph nodes (LN). mRNA has been extracted from 4 samples of LN, 4 PB and 5 BM of 6 patients with Angioimmunoblastic T-Cell Lymphoma (AITL); 2 samples of LN, 3 PB and 3 BM of 6 patients with T-cell lymphoma, not otherwise specified (PTL-NOS); 4 samples of LN, 5 PB and 3 BM of 5 patients with Anaplastic Large Cell Lymphoma ALK-positive (ALTCL ALK+); 2 samples of PB and 3 BM of 3 patients with Anaplastic Large Cell Lymphoma ALK-negative (ALTCL ALK-). Statistical analysis was carried out using χ2.
Results
We observed the PRAME (in 1 of 4 cases) and SSX1 (1/4) expression in LN of patients with AITL. SCP1 (1/4), SEMG1 (1/4) and SSX1 (2/4) were expressed in PB of these patients. SCP1 (1/5), SEMG1 (1/5), SPANXA1 (1/5) and SSX1 (2/5) were expressed in BM of patients with AITL. We detected GAGE (1/2) SEMG1 (1/2) SSX1 (1/2) and PRAME (2/2) in LN, GAGE (1/3), SEMG1 (1/3), SSX1 (1/3) and PRAME (2/3) in PB of patients with PTL-NOS. It is interesting that GAGE, SEMG1, SSX1 and PRAME were expressed together in LN and PB of one patient. There wasn’t any CTG expression in BM of PTL-NOS patients. PASD1 (1/4), SCP1 (2/4) and PRAME (4/4) mRNA were expressed in LN; NY-ESO-1 (1/5), PASD1 (1/5), SCP1 (1/5), SEMG1 (2/5), SPANXA1 (1/5) and PRAME (2/5) were expressed in PB, GAGE (1/3), NY-ESO-1 (1/3), PASD1 (1/3), SCP1 (2/3), SEMG1 (2/3), SPANXA1 (1/3) and PRAME (1/3) were expressed in BM of ALTCL ALK+ patients. SCP1 (1/2) and SPANXA1 (1/2) were expressed in PB and GAGE (1/3), SCP1 (1/3) and SEMG1 (1/3). Expression of CTG occurred only in BM of patients with histologically proven tumor involvement. PRAME expression was observed in LN more frequently, than in PB (p=0,0841) and BM (p=0,0194). All other CTG were expressed with similar frequency in LN, PB and BM.
Summary
T-cell lymphomas have a different CTG expression profile. PRAME expression was predominantly observed in lymph nodes and could be considered like a potential target in relapsed or resistant cases of T-cell lymphomas.
Keyword(s): Cancer testis antigen, T cell lymphoma
Session topic: Publication Only
Type: Publication Only
Background
Several types of T-cell lymphomas are characterized by a high risk of relapse after standard chemotherapy. It continues to be reasonable to investigate potential targets for immunotherapy in T-cell lymphomas. CTG are expressed in some hematologic malignancies. Nowadays there are a few information about the CTG expression in T-cell lymphomas.
Aims
To investigate the expression profile of CTG in T-cell lymphomas.
Methods
We used RQ PCR to evaluate mRNA expression of CTG’s HAGE, NY-ESO-1, MAGEA1, PASD1, SCP1, SEMG1, SPANXA1, SSX1 and PRAME relatively gene Abl. Systems of specific primers and fluorescent probes were used for each gene. mRNA has been extracted from peripheral blood (PB), marrow (BM) and lymph nodes (LN). mRNA has been extracted from 4 samples of LN, 4 PB and 5 BM of 6 patients with Angioimmunoblastic T-Cell Lymphoma (AITL); 2 samples of LN, 3 PB and 3 BM of 6 patients with T-cell lymphoma, not otherwise specified (PTL-NOS); 4 samples of LN, 5 PB and 3 BM of 5 patients with Anaplastic Large Cell Lymphoma ALK-positive (ALTCL ALK+); 2 samples of PB and 3 BM of 3 patients with Anaplastic Large Cell Lymphoma ALK-negative (ALTCL ALK-). Statistical analysis was carried out using χ2.
Results
We observed the PRAME (in 1 of 4 cases) and SSX1 (1/4) expression in LN of patients with AITL. SCP1 (1/4), SEMG1 (1/4) and SSX1 (2/4) were expressed in PB of these patients. SCP1 (1/5), SEMG1 (1/5), SPANXA1 (1/5) and SSX1 (2/5) were expressed in BM of patients with AITL. We detected GAGE (1/2) SEMG1 (1/2) SSX1 (1/2) and PRAME (2/2) in LN, GAGE (1/3), SEMG1 (1/3), SSX1 (1/3) and PRAME (2/3) in PB of patients with PTL-NOS. It is interesting that GAGE, SEMG1, SSX1 and PRAME were expressed together in LN and PB of one patient. There wasn’t any CTG expression in BM of PTL-NOS patients. PASD1 (1/4), SCP1 (2/4) and PRAME (4/4) mRNA were expressed in LN; NY-ESO-1 (1/5), PASD1 (1/5), SCP1 (1/5), SEMG1 (2/5), SPANXA1 (1/5) and PRAME (2/5) were expressed in PB, GAGE (1/3), NY-ESO-1 (1/3), PASD1 (1/3), SCP1 (2/3), SEMG1 (2/3), SPANXA1 (1/3) and PRAME (1/3) were expressed in BM of ALTCL ALK+ patients. SCP1 (1/2) and SPANXA1 (1/2) were expressed in PB and GAGE (1/3), SCP1 (1/3) and SEMG1 (1/3). Expression of CTG occurred only in BM of patients with histologically proven tumor involvement. PRAME expression was observed in LN more frequently, than in PB (p=0,0841) and BM (p=0,0194). All other CTG were expressed with similar frequency in LN, PB and BM.
Summary
T-cell lymphomas have a different CTG expression profile. PRAME expression was predominantly observed in lymph nodes and could be considered like a potential target in relapsed or resistant cases of T-cell lymphomas.
Keyword(s): Cancer testis antigen, T cell lymphoma
Session topic: Publication Only
Abstract: PB1940
Type: Publication Only
Background
Several types of T-cell lymphomas are characterized by a high risk of relapse after standard chemotherapy. It continues to be reasonable to investigate potential targets for immunotherapy in T-cell lymphomas. CTG are expressed in some hematologic malignancies. Nowadays there are a few information about the CTG expression in T-cell lymphomas.
Aims
To investigate the expression profile of CTG in T-cell lymphomas.
Methods
We used RQ PCR to evaluate mRNA expression of CTG’s HAGE, NY-ESO-1, MAGEA1, PASD1, SCP1, SEMG1, SPANXA1, SSX1 and PRAME relatively gene Abl. Systems of specific primers and fluorescent probes were used for each gene. mRNA has been extracted from peripheral blood (PB), marrow (BM) and lymph nodes (LN). mRNA has been extracted from 4 samples of LN, 4 PB and 5 BM of 6 patients with Angioimmunoblastic T-Cell Lymphoma (AITL); 2 samples of LN, 3 PB and 3 BM of 6 patients with T-cell lymphoma, not otherwise specified (PTL-NOS); 4 samples of LN, 5 PB and 3 BM of 5 patients with Anaplastic Large Cell Lymphoma ALK-positive (ALTCL ALK+); 2 samples of PB and 3 BM of 3 patients with Anaplastic Large Cell Lymphoma ALK-negative (ALTCL ALK-). Statistical analysis was carried out using χ2.
Results
We observed the PRAME (in 1 of 4 cases) and SSX1 (1/4) expression in LN of patients with AITL. SCP1 (1/4), SEMG1 (1/4) and SSX1 (2/4) were expressed in PB of these patients. SCP1 (1/5), SEMG1 (1/5), SPANXA1 (1/5) and SSX1 (2/5) were expressed in BM of patients with AITL. We detected GAGE (1/2) SEMG1 (1/2) SSX1 (1/2) and PRAME (2/2) in LN, GAGE (1/3), SEMG1 (1/3), SSX1 (1/3) and PRAME (2/3) in PB of patients with PTL-NOS. It is interesting that GAGE, SEMG1, SSX1 and PRAME were expressed together in LN and PB of one patient. There wasn’t any CTG expression in BM of PTL-NOS patients. PASD1 (1/4), SCP1 (2/4) and PRAME (4/4) mRNA were expressed in LN; NY-ESO-1 (1/5), PASD1 (1/5), SCP1 (1/5), SEMG1 (2/5), SPANXA1 (1/5) and PRAME (2/5) were expressed in PB, GAGE (1/3), NY-ESO-1 (1/3), PASD1 (1/3), SCP1 (2/3), SEMG1 (2/3), SPANXA1 (1/3) and PRAME (1/3) were expressed in BM of ALTCL ALK+ patients. SCP1 (1/2) and SPANXA1 (1/2) were expressed in PB and GAGE (1/3), SCP1 (1/3) and SEMG1 (1/3). Expression of CTG occurred only in BM of patients with histologically proven tumor involvement. PRAME expression was observed in LN more frequently, than in PB (p=0,0841) and BM (p=0,0194). All other CTG were expressed with similar frequency in LN, PB and BM.
Summary
T-cell lymphomas have a different CTG expression profile. PRAME expression was predominantly observed in lymph nodes and could be considered like a potential target in relapsed or resistant cases of T-cell lymphomas.
Keyword(s): Cancer testis antigen, T cell lymphoma
Session topic: Publication Only
Type: Publication Only
Background
Several types of T-cell lymphomas are characterized by a high risk of relapse after standard chemotherapy. It continues to be reasonable to investigate potential targets for immunotherapy in T-cell lymphomas. CTG are expressed in some hematologic malignancies. Nowadays there are a few information about the CTG expression in T-cell lymphomas.
Aims
To investigate the expression profile of CTG in T-cell lymphomas.
Methods
We used RQ PCR to evaluate mRNA expression of CTG’s HAGE, NY-ESO-1, MAGEA1, PASD1, SCP1, SEMG1, SPANXA1, SSX1 and PRAME relatively gene Abl. Systems of specific primers and fluorescent probes were used for each gene. mRNA has been extracted from peripheral blood (PB), marrow (BM) and lymph nodes (LN). mRNA has been extracted from 4 samples of LN, 4 PB and 5 BM of 6 patients with Angioimmunoblastic T-Cell Lymphoma (AITL); 2 samples of LN, 3 PB and 3 BM of 6 patients with T-cell lymphoma, not otherwise specified (PTL-NOS); 4 samples of LN, 5 PB and 3 BM of 5 patients with Anaplastic Large Cell Lymphoma ALK-positive (ALTCL ALK+); 2 samples of PB and 3 BM of 3 patients with Anaplastic Large Cell Lymphoma ALK-negative (ALTCL ALK-). Statistical analysis was carried out using χ2.
Results
We observed the PRAME (in 1 of 4 cases) and SSX1 (1/4) expression in LN of patients with AITL. SCP1 (1/4), SEMG1 (1/4) and SSX1 (2/4) were expressed in PB of these patients. SCP1 (1/5), SEMG1 (1/5), SPANXA1 (1/5) and SSX1 (2/5) were expressed in BM of patients with AITL. We detected GAGE (1/2) SEMG1 (1/2) SSX1 (1/2) and PRAME (2/2) in LN, GAGE (1/3), SEMG1 (1/3), SSX1 (1/3) and PRAME (2/3) in PB of patients with PTL-NOS. It is interesting that GAGE, SEMG1, SSX1 and PRAME were expressed together in LN and PB of one patient. There wasn’t any CTG expression in BM of PTL-NOS patients. PASD1 (1/4), SCP1 (2/4) and PRAME (4/4) mRNA were expressed in LN; NY-ESO-1 (1/5), PASD1 (1/5), SCP1 (1/5), SEMG1 (2/5), SPANXA1 (1/5) and PRAME (2/5) were expressed in PB, GAGE (1/3), NY-ESO-1 (1/3), PASD1 (1/3), SCP1 (2/3), SEMG1 (2/3), SPANXA1 (1/3) and PRAME (1/3) were expressed in BM of ALTCL ALK+ patients. SCP1 (1/2) and SPANXA1 (1/2) were expressed in PB and GAGE (1/3), SCP1 (1/3) and SEMG1 (1/3). Expression of CTG occurred only in BM of patients with histologically proven tumor involvement. PRAME expression was observed in LN more frequently, than in PB (p=0,0841) and BM (p=0,0194). All other CTG were expressed with similar frequency in LN, PB and BM.
Summary
T-cell lymphomas have a different CTG expression profile. PRAME expression was predominantly observed in lymph nodes and could be considered like a potential target in relapsed or resistant cases of T-cell lymphomas.
Keyword(s): Cancer testis antigen, T cell lymphoma
Session topic: Publication Only
{{ help_message }}
{{filter}}